title: Prognostic value of pretreatment 18F-fluorodeoxyglucose positron emission tomography/CT volume-based parameters in patients with oropharyngeal squamous cell carcinoma with known p16 and p53 status.
abstract: BACKGROUND
  The purpose of this study was to determine whether pretreatment 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG PET/CT) volume-based parameters, such as metabolic tumor volume and total lesion glycolysis, add more prognostic information in patients with oropharyngeal squamous cell carcinoma (SCC).
  
  
  METHODS
  The subjects were 47 patients with oropharyngeal SCC who underwent 18F-FDG PET/CT before any treatment and followed by definitive therapy. PET parameters (metabolic tumor volume and total lesion glycolysis) and tumor p16/p53 status were evaluated retrospectively. Univariate and multivariate analyses were performed for disease-free survival (DFS), disease-specific survival (DSS), and overall survival (OS).
  
  
  RESULTS
  All volume-based PET parameters were found to be significant prognostic factors for DFS, DSS, and OS in univariate analysis. In multivariate analysis, only metabolic tumor volume for total tumor lesions (cutoff 65) retained an independent association with DFS, DSS, and OS.
  
  
  CONCLUSIONS
  Metabolic tumor volume for total tumor lesions may be a predictive marker for survival outcomes in patients with oropharyngeal SCC with known p16/p53 status.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe City, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kikuchi
authors.affiliation: Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kobe City, Japan.
authors.forename: Sho
authors.initials: S
authors.lastname: Koyasu
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe City, Japan.
authors.forename: Shogo
authors.initials: S
authors.lastname: Shinohara
authors.affiliation: Department of Clinical Laboratory, Osaka University Dental Hospital, Osaka, Japan.
authors.forename: Yu
authors.initials: Y
authors.lastname: Usami
authors.affiliation: Department of Clinical Pathology, Kobe City Medical Center General Hospital, Kobe City, Japan.
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Imai
authors.affiliation: Department of Radiology, Kobe City Medical Center General Hospital, Kobe City, Japan.
authors.forename: Megumu
authors.initials: M
authors.lastname: Hino
authors.affiliation: Department of Radiology, Kobe City Medical Center General Hospital, Kobe City, Japan.
authors.forename: Kyo
authors.initials: K
authors.lastname: Itoh
authors.affiliation: Institute of Biomedical Research and Innovation, Kobe City, Japan.
authors.forename: Risa
authors.initials: R
authors.lastname: Tona
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe City, Japan.
authors.forename: Yuji
authors.initials: Y
authors.lastname: Kanazawa
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe City, Japan.
authors.forename: Ippei
authors.initials: I
authors.lastname: Kishimoto
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe City, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Harada
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe City, Japan.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Naito
mesh_terms: D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D054893:Cone-Beam Computed Tomography; D019941:Cyclin-Dependent Kinase Inhibitor p16; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000008:administration & dosage*; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism*; D009367:Neoplasm Staging; D009959:Oropharyngeal Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D016016:Proportional Hazards Models; D019275:Radiopharmaceuticals / Q000008:administration & dosage; D012189:Retrospective Studies; D000077195:Squamous Cell Carcinoma of Head and Neck; D015996:Survival Rate; D014057:Tomography, X-Ray Computed / Q000379:methods*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
chemical_list: C000614131:CDKN2A protein, human; D019941:Cyclin-Dependent Kinase Inhibitor p16; D009363:Neoplasm Proteins; D019275:Radiopharmaceuticals; D016159:Tumor Suppressor Protein p53; D019788:Fluorodeoxyglucose F18
keywords: 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT; human papillomavirus (HPV); oropharyngeal squamous cell carcinoma; p16; p53